NJ-EXPERIC
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced its new facility in Dublin, Ireland, to support global clinical trials. The opening of this depot will expand the Company’s global footprint, increase the efficiency of its worldwide clinical trial supply services, and facilitate future growth.
At the forefront of this expansion effort is Experic's Vice President of Operations, Brian Fagan. "Experic is a company that listens to its customers,” shared the 25+ year clinical trial supply veteran. “When customers voiced their preference for more clinical trial supply services under the Experic umbrella – we listened - and made it a strategic priority to expand direct management of these services in Europe.”
The new Experic depot will do just that thanks to its geographical proximity to European markets and North America. The secure, 10,000 sq. ft. warehouse space will provide monitored storage and logistics services, including cold storage and re-labeling capabilities, for the rapid and reliable distribution of Investigational Medicinal Products (IMPs) and comparators for pharmaceutical companies conducting global clinical trials with investigator sites and patients across Europe. Opening in the second half of 2024, the depot activities will be carried out by local talent that is familiar with EU regulatory requirements, with the support of Experic’s expert project management team in the United States and the Company’s current Global Partner Depot Network.
This facility serves as the company's first physical expansion of business into the EU and will ultimately contribute to the efficiency and success of trial services.
If you would like to request a meeting with Experic at Clinical Trial Supply Europe in Barcelona next month, please go here.
About Experic:
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats. From our state-of-the-art, cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Learn more about our manufacturing and clinical trial supply services at expericservices.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227449218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelera Announces Europa AIPU, Setting New Industry Benchmark for AI Accelerator Performance, Power Efficiency and Affordability21.10.2025 14:00:00 CEST | Press release
Delivers 629 TOPs processing power for multi-modal AI applications from the edge to the data center Axelera AI, the leading provider of purpose-built AI hardware acceleration technology, today announced Europa™, an AI processor unit (AIPU) that sets a new performance/price standard for multi-user generative AI and computer vision applications. Europa’s combination of processing power, energy and thermal efficiency, compact packaging, and multiple form factor options make it ideal for compute-intensive, multi-modal AI inference applications from the edge to enterprise servers. Designed to be cost effective and accessible, Europa enables any organization to unlock the power of cutting-edge AI applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021493990/en/ Europa™ AIPU Next Gen Architecture for Real World AI Processing Power The Europa AIPU features eight second-generation AI cores, each incorporating Axelera’s ad
Enedym Inc. Secures Investment from Honda Motor Co., Ltd.21.10.2025 14:00:00 CEST | Press release
Enedym’s next generation switched reluctance motor (SRM) drive technology requires no permanent magnets or rare earth metals Enedym Inc. (“Enedym”), a technology company thatdevelops next generation switched reluctance motors (SRMs), electric powertrains, and powertrain controls, announced today an investment from Honda Motor Co., Ltd. (“Honda”). Honda invests in innovative startups through its global open innovation program, Honda Xcelerator Ventures. The new investment will be used to accelerate Enedym’s patented motor technology development and ramp up its operations. Enedym is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 70 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair Laureate Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. The Company is focused on the development of electric motors completely f
ExaGrid Named Finalist for the MSP Channel Awards 202521.10.2025 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Inaugural Industry Awards ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it has been nominated in six categories for the 1st annual MSP Channel Awards, which celebrates innovation across the IT Channel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021571422/en/ The new MSP Channel Awards build on the legacy of the former SDC Awards to better reflect today's fast-moving IT landscape. As managed services reshape how technology is delivered – from digital transformation and cybersecurity to cloud, data, and automation – these awards recognize the companies, partnerships, and individuals making a real impact across the channel. Voting to determine the winner in each category i
Carevance platform expands access to GE HealthCare’s clinical excellence with advanced patient monitoring and new perioperative hypotension management capability21.10.2025 14:00:00 CEST | Press release
Built on GE HealthCare’s 50+ years of clinical excellence in patient monitoring, Carevance is an advanced, reliable monitoring solution that leverages proprietary algorithms and proven technologies to help hospitals and clinicians deliver consistent, high-quality care. Designed for today’s clinical realities, Carevance helps support clinicians across acute care areas through an enhanced intra-hospital transport workflow and real-time patient data. As part of its capabilities, Carevance introduces the new Cardiac Output Insights feature available directly on the device to support caregivers in managing hemodynamic instability for perioperative care and help enable timely clinical interventions. Hemodynamic instability or hypotension is a common concern for care teams to manage during and after surgery, and can be associated with longer hospital stays and serious postoperative complications, such as organ failure and mortality.i,ii GE HealthCare (Nasdaq: GEHC) today announced it has rece
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital21.10.2025 14:00:00 CEST | Press release
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, today announced a majority investment by Curewell Capital (“Curewell”), a Los Angeles-based private equity firm focused on building industry-leading healthcare companies. Hui-Yin “Harry” Li, Ph.D., Founder and CEO of WPT, will retain a significant ownership stake and will continue to lead the business alongside the management team. The partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021135557/en/ Founded in 2003, WPT has built extensive expertise across hundreds of novel drug substance programs, spanning complex synthesis, med
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom